Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma

Drug Profile

Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma

Alternative Names: ADA 308; ADA 409; Backup; Backup I; Backup II; MDA-308; MDA-409

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medeia Therapeutics
  • Developer Aranda Pharma; Tarrex Biopharma
  • Class Antineoplastics; Cytoprotectives; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preclinical Parkinson's disease; Prostate cancer
  • Research Neurodegenerative disorders; Peripheral ischaemia

Most Recent Events

  • 24 Aug 2017 Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma is available for licensing as of 24 Aug 2017.
  • 23 Aug 2017 Aranda Pharma has patent protection for androgen receptor targeting small molecules in USA and European Union
  • 24 Mar 2017 Early research in Peripheral ischaemia in Finland (unspecified route) (Aranda Pharma pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top